Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ONTX

ONTX - Onconova Therapeutics Inc Stock Price, Fair Value and News

$2.46-0.36 (-12.77%)
Market Closed

5/100

ONTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

5/100

ONTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.94

Target 3M

$2.18

Target 6M

$2.06

ONTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ONTX Price Action

Last 7 days

1.2%

Last 30 days

117.7%

Last 90 days

-6.8%

Trailing 12 Months

-66.7%

ONTX RSI Chart

ONTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ONTX Valuation

Market Cap

19.7M

Price/Earnings (Trailing)

-1.48

Price/Sales (Trailing)

66.83

EV/EBITDA

-0.54

Price/Free Cashflow

-1.01

ONTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.94

Target 3M

$2.18

Target 6M

$2.06

ONTX Fundamentals

ONTX Revenue

Revenue (TTM)

226.0K

ONTX Earnings

Earnings (TTM)

-13.3M

Earnings Growth (Yr)

53.25%

Earnings Growth (Qtr)

-333.01%

ONTX Profitability

EBT Margin

-7151.77%

Return on Equity

-292.83%

Return on Assets

-106.96%

Free Cashflow Yield

-99.03%

ONTX Investor Care

Shares Dilution (1Y)

164.11%

Diluted EPS (TTM)

-3.67

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
2024226.0K226.0K226.0K0
2023226.0K226.0K226.0K226.0K
2022226.0K226.0K226.0K226.0K
2021235.0K236.0K227.0K226.0K
20202.2M201.0K204.0K231.0K
20191.5M1.7M1.9M2.2M
20181.1M1.3M1.3M1.2M
20174.3M2.4M817.0K787.0K
201612.8M14.9M15.0M5.5M
2015467.0K465.0K2.0M11.5M
20144.1M3.6M2.6M800.0K
201346.8M47.5M5.8M4.8M
201212.7M23.8M35.0M46.2M
20110001.5M
Get all data in R, Python etc through our Historical Stock Data APIs

About Onconova Therapeutics Inc

ONTX
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
 CEO
 WEBSITEonconova.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES16

Onconova Therapeutics Inc Frequently Asked Questions

ONTX is the stock ticker symbol of Onconova Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Onconova Therapeutics Inc is 19.66 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ONTX's fair value in chart for subscribers.

The fair value guage provides a quick view whether ONTX is over valued or under valued. Whether Onconova Therapeutics Inc is cheap or expensive depends on the assumptions which impact Onconova Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ONTX.

As of Wed Jan 28 2026, ONTX's PE ratio (Price to Earnings) is -1.48 and Price to Sales (PS) ratio is 66.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ONTX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Onconova Therapeutics Inc has provided -0.47 (multiply by 100 for percentage) rate of return.